Assembly Biosciences, Inc. ASMB NASDAQ

Assembly Biosciences, Inc. (ASMB) reported total assets of $257.59M and total liabilities of $50.84M for fiscal year 2025, resulting in total equity of $206.75M.

The company held $248.11M in cash and short-term investments. Total debt stood at $2.63M, with net debt of $-55.82M. The Debt-to-Equity (D/E) ratio was 0.01 (conservative).

Current ratio is 5.22, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.01, current ratio of 5.22 — balance sheet is strong
• MOAT (50/100) — Total assets $257.59M and equity $206.75M support the company's competitive scale
• VALUE (90/100) — Debt-to-Equity 0.01 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 59/100 with 4/7 criteria passed.

NUVB

Nuvation Bio Inc.

$4.82

-0.72%

CTMX

CytomX Therapeutics, Inc.

$4.56

+0.44%

SPRO

Spero Therapeutics, Inc.

$2.64

-5.04%

ACHL

Achilles Therapeutics plc

$1.48

+0.68%

TIL

Instil Bio, Inc.

$8.89

+5.33%

NXTC

NextCure, Inc.

$12.02

-5.87%

NLTX

Neoleukin Therapeutics, Inc.

$3.49

+1.45%

LLY

Eli Lilly and Company

$905.13

-1.88%